Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2020

Open Access 01-12-2020 | Hypertension | Original investigation

Blood pressure levels and cardiovascular risk according to age in patients with diabetes mellitus: a nationwide population-based cohort study

Authors: Hack-Lyoung Kim, Hyue Mee Kim, Chang Hee Kwon, Jeong-Hun Shin, Mi-Hyang Jung, Chan Joo Lee, Dae-Hee Kim, Woo-Hyeun Kim, Si-Hyuck Kang, Ju-Hee Lee, In Jeong Cho, Iksung Cho, Jun Hyeok Lee, Dae Ryong Kang, Hae-Young Lee, Wook-Jin Chung, Sang-Hyun Ihm, Kwang Il Kim, Eun Joo Cho, Il-Suk Sohn, Hyeon-Chang Kim, Jinho Shin, Ju Han Kim, Sung Kee Ryu, Seok-Min Kang, Wook Bum Pyun, Myeong-Chan Cho, Sungha Park, Ki-Chul Sung

Published in: Cardiovascular Diabetology | Issue 1/2020

Login to get access

Abstract

Background

Little is known about age-specific target blood pressure (BP) in hypertensive patients with diabetes mellitus (DM). The aim of this study was to determine the BP level at the lowest cardiovascular risk of hypertensive patients with DM according to age.

Methods

Using the Korean National Health Insurance Service database, we analyzed patients without cardiovascular disease diagnosed with both hypertension and DM from January 2002 to December 2011. Primary end-point was composite cardiovascular events including cardiovascular death, myocardial infarction and stroke.

Results

Of 241,148 study patients, 35,396 had cardiovascular events during a median follow-up period of 10 years. At the age of < 70 years, the risk of cardiovascular events was lower in patients with BP < 120/70 mmHg than in those with BP 130–139/80–89 mmHg. At the age of ≥ 70, however, there were no significant differences in the risk of cardiovascular events between patients with BP 130–139/80–89 mmHg and BP < 120/70 mmHg. The risk of cardiovascular events was similar between patients with BP 130–139/80–89 mmHg and BP 120–129/70–79 mmHg, and it was significantly higher in those with BP ≥ 140/90 mmHg than in those with BP 130–139/80–89 mmHg at all ages.

Conclusions

In a cohort of hypertensive patients who had DM but no history of cardiovascular disease, lower BP was associated with lower risk of cardiovascular events especially at the age of < 70. However, low BP < 130–139/80–89 mmHg was not associated with decreased cardiovascular risk, it may be better to keep the BP of 130–139/80–89 mmHg at the age of ≥ 70.
Appendix
Available only for authorised users
Literature
1.
go back to reference Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37–55. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37–55.
2.
go back to reference Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602.
3.
go back to reference Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–8.CrossRef Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–8.CrossRef
4.
go back to reference Flint AC, Conell C, Ren X, et al. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med. 2019;381:243–51.CrossRef Flint AC, Conell C, Ren X, et al. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med. 2019;381:243–51.CrossRef
5.
go back to reference Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46:760–5.CrossRef Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46:760–5.CrossRef
6.
go back to reference Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009;53:S35-42.CrossRef Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009;53:S35-42.CrossRef
7.
go back to reference Klein R, Klein BE, Lee KE, et al. The incidence of hypertension in insulin-dependent diabetes. Arch Intern Med. 1996;156:622–7.CrossRef Klein R, Klein BE, Lee KE, et al. The incidence of hypertension in insulin-dependent diabetes. Arch Intern Med. 1996;156:622–7.CrossRef
8.
go back to reference Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9.CrossRef Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9.CrossRef
9.
go back to reference Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644–50.CrossRef Wannamethee SG, Shaper AG, Lennon L, et al. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005;165:2644–50.CrossRef
10.
go back to reference Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053–9.CrossRef Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053–9.CrossRef
11.
go back to reference Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.CrossRef Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.CrossRef
12.
go back to reference Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.CrossRef Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.CrossRef
13.
go back to reference Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315:2673–82.CrossRef Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016;315:2673–82.CrossRef
14.
go back to reference Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res. 2019;124:1045–60.CrossRef Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older patients. Circ Res. 2019;124:1045–60.CrossRef
15.
go back to reference Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:e13–115.PubMed Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71:e13–115.PubMed
16.
go back to reference Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.CrossRef Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–104.CrossRef
17.
go back to reference Seong SC, Kim YY, Park SK, et al. Cohort profile: the National Health Insurance Service- National Health Screening Cohort (NHIS-HEALS) in Korea. BMJ Open. 2017;7:e016640.CrossRef Seong SC, Kim YY, Park SK, et al. Cohort profile: the National Health Insurance Service- National Health Screening Cohort (NHIS-HEALS) in Korea. BMJ Open. 2017;7:e016640.CrossRef
18.
go back to reference Park TH, Choi JC. Validation of stroke and thrombolytic therapy in Korean National Health Insurance claim data. J Clin Neurol. 2016;12:42–8.CrossRef Park TH, Choi JC. Validation of stroke and thrombolytic therapy in Korean National Health Insurance claim data. J Clin Neurol. 2016;12:42–8.CrossRef
19.
go back to reference Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.CrossRef Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.CrossRef
20.
go back to reference Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.CrossRef Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.CrossRef
21.
go back to reference Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799–810.CrossRef Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799–810.CrossRef
22.
go back to reference Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10-should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922–44.CrossRef Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10-should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922–44.CrossRef
23.
go back to reference Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;29:1253–69.CrossRef Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011;29:1253–69.CrossRef
24.
go back to reference Margolis KL, O’Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721–8.CrossRef Margolis KL, O’Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37:1721–8.CrossRef
25.
go back to reference Brunstrom M, Carlberg BO. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:717.CrossRef Brunstrom M, Carlberg BO. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:717.CrossRef
26.
go back to reference Edmin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systemic review and meta-analysis. JAMA. 2015;313:603–15.CrossRef Edmin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systemic review and meta-analysis. JAMA. 2015;313:603–15.CrossRef
27.
go back to reference Messerli FH, Bangalore S, Messerli AW. Age, blood pressure targets, and guidelines: rift between those who preach, those who teach, and those who treat? Circulation. 2018;138:128–30.CrossRef Messerli FH, Bangalore S, Messerli AW. Age, blood pressure targets, and guidelines: rift between those who preach, those who teach, and those who treat? Circulation. 2018;138:128–30.CrossRef
28.
go back to reference Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.CrossRef Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.CrossRef
29.
go back to reference Cardiovascular disease and risk management. standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S103–23.CrossRef Cardiovascular disease and risk management. standards of medical care in diabetes-2019. Diabetes Care. 2019;42:S103–23.CrossRef
30.
go back to reference Shen Y, Dai Y, Wang XQ, et al. Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease. Cardiovasc Diabetol. 2019;18:160.CrossRef Shen Y, Dai Y, Wang XQ, et al. Searching for optimal blood pressure targets in type 2 diabetic patients with coronary artery disease. Cardiovasc Diabetol. 2019;18:160.CrossRef
31.
go back to reference Solini A, Grossman E. What should be the target blood pressure in elderly patients with diabetes? Diabetes Care. 2016;39(Suppl 2):S234–43.CrossRef Solini A, Grossman E. What should be the target blood pressure in elderly patients with diabetes? Diabetes Care. 2016;39(Suppl 2):S234–43.CrossRef
32.
go back to reference Sternlicht H, Basile J. Hypertension in the elderly: recent developments and insights. Curr Opin Cardiol. 2020;35:351–6.PubMed Sternlicht H, Basile J. Hypertension in the elderly: recent developments and insights. Curr Opin Cardiol. 2020;35:351–6.PubMed
33.
go back to reference Quan H, Khan N, Hemmelgarn BR, et al. Validation of a case definition to define hypertension using administrative data. Hypertension. 2009;54:1423–8.CrossRef Quan H, Khan N, Hemmelgarn BR, et al. Validation of a case definition to define hypertension using administrative data. Hypertension. 2009;54:1423–8.CrossRef
34.
go back to reference Dolan E, Stanton A, Thijis L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156–61.CrossRef Dolan E, Stanton A, Thijis L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156–61.CrossRef
Metadata
Title
Blood pressure levels and cardiovascular risk according to age in patients with diabetes mellitus: a nationwide population-based cohort study
Authors
Hack-Lyoung Kim
Hyue Mee Kim
Chang Hee Kwon
Jeong-Hun Shin
Mi-Hyang Jung
Chan Joo Lee
Dae-Hee Kim
Woo-Hyeun Kim
Si-Hyuck Kang
Ju-Hee Lee
In Jeong Cho
Iksung Cho
Jun Hyeok Lee
Dae Ryong Kang
Hae-Young Lee
Wook-Jin Chung
Sang-Hyun Ihm
Kwang Il Kim
Eun Joo Cho
Il-Suk Sohn
Hyeon-Chang Kim
Jinho Shin
Ju Han Kim
Sung Kee Ryu
Seok-Min Kang
Wook Bum Pyun
Myeong-Chan Cho
Sungha Park
Ki-Chul Sung
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2020
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-020-01156-8

Other articles of this Issue 1/2020

Cardiovascular Diabetology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine